DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
Halozyme Therapeutics
HALO
Teradata Corp
TDC
Collegium Pharmaceutical
COLL
Hutchmed (China)
HCM
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 27.32%364M | 0.34%236.9M | -3.70%263M | 16.43%1.03B | -32.93%235.5M | 27.81%285.9M | 49.81%236.1M | 78.73%273.1M | -10.93%885.2M | 3.20%351.1M |
Net income from continuing operations | -142.31%-75.1M | 10.08%243.5M | 12.06%227.7M | 82.56%755.6M | 193.32%153.7M | -5.13%177.5M | 18.23%221.2M | -0.59%203.2M | -49.98%413.9M | -204.17%-164.7M |
Operating gains losses | -76.47%-3M | -55.00%-3.1M | 75.00%-1.1M | 29.27%-8.7M | 73.91%-600K | 54.05%-1.7M | 48.72%-2M | -83.33%-4.4M | -30.85%-12.3M | -15.00%-2.3M |
Depreciation and amortization | 7.12%60.2M | 6.81%59.6M | 4.92%57.6M | 2.83%225.2M | -0.17%58.3M | 5.44%56.2M | 4.10%55.8M | 2.23%54.9M | -0.05%219M | 7.75%58.4M |
Deferred tax | -1,963.41%-84.6M | -1,966.67%-6.2M | 25.00%-1.2M | 88.28%-13.8M | 92.57%-7.8M | 72.85%-4.1M | -108.82%-300K | -60.00%-1.6M | -679.80%-117.7M | -740.00%-105M |
Other non cash items | 17.65%2M | 400.00%2.4M | 170.00%2.7M | 87.50%-400K | -35.29%-2.3M | -5.56%1.7M | 55.56%-800K | 166.67%1M | 96.61%-3.2M | 22.73%-1.7M |
Change In working capital | 124.34%93.1M | -38.97%-73.1M | -475.82%-52.4M | 86.50%-9.3M | -92.28%10.9M | 632.05%41.5M | 46.44%-52.6M | 91.26%-9.1M | -298.27%-68.9M | 13.50%141.2M |
-Change in receivables | 826.00%36.3M | -40.67%-42.2M | -733.33%-20M | -1,737.74%-97.4M | -1,566.67%-60M | -186.21%-5M | -426.32%-30M | -33.33%-2.4M | -320.83%-5.3M | -125.00%-3.6M |
-Change in inventory | -13,300.00%-26.8M | -24.62%-24.3M | 435.42%16.1M | 141.49%38.5M | 5.18%63M | 98.98%-200K | 71.86%-19.5M | 92.46%-4.8M | -218.90%-92.8M | 94.48%59.9M |
-Change in payables and accrued expense | 69.11%87.6M | 0.00%-6.2M | -846.51%-40.7M | -1.66%53.4M | -87.10%12.1M | 151.46%51.8M | 72.44%-6.2M | 88.56%-4.3M | 72.38%54.3M | 1.30%93.8M |
-Change in other current assets | -4.17%2.3M | -14.81%6.9M | -842.86%-5.2M | 316.00%10.4M | 63.64%-800K | 145.28%2.4M | 17.39%8.1M | -77.42%700K | 140.98%2.5M | 81.97%-2.2M |
-Change in other working capital | 16.00%-6.3M | -46.00%-7.3M | -252.94%-2.6M | 48.55%-14.2M | 49.25%-3.4M | 18.48%-7.5M | 34.21%-5M | 141.46%1.7M | -72.50%-27.6M | -458.33%-6.7M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 27.32%364M | 0.34%236.9M | -3.70%263M | 16.43%1.03B | -32.93%235.5M | 27.81%285.9M | 49.81%236.1M | 78.73%273.1M | -10.93%885.2M | 3.20%351.1M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 21.28%-46.6M | -12.88%-44.7M | -58.11%-46.8M | 67.84%-234.3M | 83.13%-105.9M | 2.79%-59.2M | -64.32%-39.6M | -88.54%-29.6M | -6.83%-728.6M | -2.55%-627.9M |
Net PPE purchase and sale | 16.64%-48.6M | 20.68%-30.3M | -85.20%-46.3M | -25.00%-223.5M | -26.39%-102M | 1.69%-58.3M | -64.66%-38.2M | -60.26%-25M | -50.51%-178.8M | -47.53%-80.7M |
Net business purchase and sale | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- | 1.65%-546.8M | ---- |
Net other investing changes | 322.22%2M | 492.86%5.5M | 89.13%-500K | -260.00%-10.8M | -875.00%-3.9M | 43.75%-900K | -55.56%-1.4M | -4,500.00%-4.6M | 58.33%-3M | 75.00%-400K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 21.28%-46.6M | -12.88%-44.7M | -58.11%-46.8M | 67.84%-234.3M | 83.13%-105.9M | 2.79%-59.2M | -64.32%-39.6M | -88.54%-29.6M | -6.83%-728.6M | -2.55%-627.9M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -27.94%-60.9M | -1,205.41%-48.3M | 32.92%-209.1M | -500.17%-725.6M | -445.00%-362.6M | 86.71%-47.6M | -101.11%-3.7M | -53.85%-311.7M | 52.04%-120.9M | -68.47%105.1M |
Net issuance payments of debt | ---2.5M | 115.33%2.3M | 21.75%-200M | -325.69%-270.6M | --0 | --0 | -103.75%-15M | -70.51%-255.6M | -70.08%119.9M | -78.04%169.6M |
Net common stock issuance | ---- | ---- | ---- | ---300.1M | ---- | ---- | ---- | ---- | --0 | ---- |
Cash dividends paid | -3.44%-69.2M | -3.75%-69.2M | -4.07%-69M | -4.51%-266.5M | -4.39%-66.6M | -4.86%-66.9M | -4.71%-66.7M | -4.08%-66.3M | -3.03%-255M | -3.40%-63.8M |
Proceeds from stock option exercised by employees | -44.04%10.8M | -74.90%19.6M | 487.25%59.9M | 326.34%111.7M | 7.89%4.1M | 250.91%19.3M | 1,223.73%78.1M | -7.27%10.2M | -73.45%26.2M | -94.71%3.8M |
Net other financing activities | --0 | ---- | ---- | 99.17%-100K | --0 | --0 | ---- | ---- | -200.00%-12M | ---4.5M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -27.94%-60.9M | -1,205.41%-48.3M | 32.92%-209.1M | -500.17%-725.6M | -445.00%-362.6M | 86.71%-47.6M | -101.11%-3.7M | -53.85%-311.7M | 52.04%-120.9M | -68.47%105.1M |
Net cash flow | ||||||||||
Beginning cash position | 23.89%491.7M | 72.44%349.7M | 27.45%344.5M | 12.34%270.3M | 31.01%573.3M | -37.96%396.9M | 16.28%202.8M | 12.34%270.3M | 31.40%240.6M | 143.11%437.6M |
Current changes in cash | 43.22%256.5M | -25.36%143.9M | 110.41%7.1M | 98.04%70.7M | -35.70%-233M | 191.66%179.1M | -58.83%192.8M | -4.12%-68.2M | -40.20%35.7M | -380.56%-171.7M |
Effect of exchange rate changes | 244.44%3.9M | -246.15%-1.9M | -371.43%-1.9M | 158.33%3.5M | -4.55%4.2M | 59.70%-2.7M | 143.33%1.3M | 200.00%700K | -172.73%-6M | 833.33%4.4M |
End cash Position | 31.19%752.1M | 23.89%491.7M | 72.44%349.7M | 27.45%344.5M | 27.45%344.5M | 31.01%573.3M | -37.96%396.9M | 16.28%202.8M | 12.34%270.3M | 12.34%270.3M |
Free cash flow | 38.58%315.4M | 4.40%206.6M | -12.66%216.7M | 14.26%807.1M | -50.63%133.5M | 38.44%227.6M | 47.25%197.9M | 80.83%248.1M | -19.27%706.4M | -5.29%270.4M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |